Enliven Therapeutics CSO sells $84k in shares
- Investing.com
- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Enliven Therapeutics Inc (ELVN)
Assess today's live Enliven Therapeutics Inc (ELVN) share price, performance and insights using our live NASDAQ: ELVN stock exchange data.
Analyse the historical data and Enliven Therapeutics Inc share price performance charts on this page. Our technical summary section provides analysis on Enliven Therapeutics share price buy/sell indicators using real-time data (or discuss the Enliven Therapeutics (ELVN) stock price today with other investors in the Enliven Therapeutics NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ ELVN share price (ISIN: US29337E1029) to enhance your trading decisions with our free investment tools and resources.
What Is the Enliven Therapeutics Inc Share Price Today?
The Enliven Therapeutics share price today is 16.530.
What Is the Stock Symbol for Enliven Therapeutics Inc
The stock symbol (or 'ticker') for Enliven Therapeutics Inc is "ELVN."
What Stock Exchange Does Enliven Therapeutics Inc Trade On?
Enliven Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Enliven Therapeutics Inc a Good Stock to Buy?
Determining whether Enliven Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
Analyse the historical data and Enliven Therapeutics Inc share price performance charts on this page. Our technical summary section provides analysis on Enliven Therapeutics share price buy/sell indicators using real-time data (or discuss the Enliven Therapeutics (ELVN) stock price today with other investors in the Enliven Therapeutics NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ ELVN share price (ISIN: US29337E1029) to enhance your trading decisions with our free investment tools and resources.
What Is the Enliven Therapeutics Inc Share Price Today?
The Enliven Therapeutics share price today is 16.530.
What Is the Stock Symbol for Enliven Therapeutics Inc
The stock symbol (or 'ticker') for Enliven Therapeutics Inc is "ELVN."
What Stock Exchange Does Enliven Therapeutics Inc Trade On?
Enliven Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Enliven Therapeutics Inc a Good Stock to Buy?
Determining whether Enliven Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
NASDAQ
Currency in USD
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
16.475
17.880
52 wk Range
13.300
25.370
ELVN is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
16.47517.880
52 wk Range
13.30025.370
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ELVN Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
41.375
Upside
+150.30%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Suffers from weak gross profit margins
- Form 144 Enliven Therapeutics For: 19 November
- Investing.com
- Enliven Therapeutics appoints Rick Fair as new CEO
- Investing.com
- Enliven Therapeutics CSO sells $84k in shares
- Investing.com
- Enliven Therapeutics appoints Rick Fair as new CEO
- Investing.com
- Enliven Therapeutics CEO Kintz sells $272k in shares
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Enliven Therapeutics Company Profile
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a CNS penetrant and irreversible HER2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 driven cancers and solid tumors. The company is headquartered in Boulder, Colorado.
Compare ELVN to Peers and Sector
Metrics to compare | ELVN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipELVNPeersSector | |
|---|---|---|---|---|
P/E Ratio | −10.1x | −0.7x | −0.6x | |
PEG Ratio | −2.50 | −0.01 | 0.00 | |
Price/Book | 2.1x | 2.0x | 2.6x | |
Price / LTM Sales | - | 2.7x | 3.2x | |
Upside (Analyst Target) | 123.1% | 286.1% | 41.8% | |
Fair Value Upside | Unlock | 43.3% | 5.1% | Unlock |
Analyst Ratings
9 Buy
0 Hold
0 Sell
Ratings:
9 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 41.375
(+150.30% Upside)
Earnings
Latest Release
Nov 12, 2025
EPS / Forecast
-0.32 / -0.50
Revenue / Forecast
-- / --
People Also Watch
FAQ
What Is the Enliven Therapeutics (ELVN) Share Price Today?
The live Enliven Therapeutics share price today is 16.530
What Stock Exchange Does Enliven Therapeutics (ELVN) Trade On?
Enliven Therapeutics is listed and trades on the Nasdaq Stock Exchange.
What Is the Ticker (Stock Symbol) for Enliven Therapeutics?
The stock symbol (also called a 'ticker') for Enliven Therapeutics is "ELVN."
What Is the Current Enliven Therapeutics Market Cap?
As of today, Enliven Therapeutics market capitalisation is 981.01M.
What Is Enliven Therapeutics's (ELVN) Earnings Per Share (TTM)?
The Enliven Therapeutics EPS is currently -1.81 (Trailing Twelve Months).
When Is the Next Enliven Therapeutics Earnings Date?
Enliven Therapeutics's next earnings report will be released on 12 Mar 2026.
Is ELVN a Buy or Sell From a Technical Analyst Perspective?
Based on today's Enliven Therapeutics moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Enliven Therapeutics Stock Split?
Enliven Therapeutics has split 1 times. (See the ELVN stock split history page for full effective split date and price information.)
How Many Employees Does Enliven Therapeutics Have?
Enliven Therapeutics has 65 employees.
What is the current trading status of Enliven Therapeutics (ELVN)?
As of 24 Dec 2025, Enliven Therapeutics (ELVN) is trading at a price of 16.530, with a previous close of 17.930. The stock has fluctuated within a day range of 16.475 to 17.880, while its 52-week range spans from 13.300 to 25.370.
What Is Enliven Therapeutics (ELVN) Price Target According to Analysts?
The average 12-month price target for Enliven Therapeutics is USD41.375, with a high estimate of USD52 and a low estimate of USD33. 9 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +150.30% Upside potential.
What Is the ELVN Premarket Price?
ELVN's last pre-market stock price is 17.650. The pre-market share volume is 2,980.000, and the stock has decreased by -0.280, or -1.560%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.